Gujarat Magazine

Beta-thalassemia Market Is Predicted to Exhibit Remarkable Growth | Acceleron Pharma, Agios Pharmaceuticals, Inc., Allife Medical Science and Technology, Aruvant Sciences, Beam Therapeutics, Bioray

 Breaking News
  • No posts were found

Beta-thalassemia Market Is Predicted to Exhibit Remarkable Growth | Acceleron Pharma, Agios Pharmaceuticals, Inc., Allife Medical Science and Technology, Aruvant Sciences, Beam Therapeutics, Bioray

June 19
09:15 2024
Beta-thalassemia Market Is Predicted to Exhibit Remarkable Growth | Acceleron Pharma, Agios Pharmaceuticals, Inc., Allife Medical Science and Technology, Aruvant Sciences, Beam Therapeutics, Bioray
Beta-thalassemia Market
As per DelveInsight, the Beta-thalassemia Market is anticipated to evolve immensely in the coming years owing to the rise in the prevalence of Beta-thalassemia and the anticipated launch of novel therapies in the market.

To counter unmet market needs and provide better treatment choices for beta-thalassemia, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the near future, likely to drive market growth during the study period. Bluebird Bio, Agios Pharmaceutical, Ionis Pharmaceutical, and others are the leading pharma and biotech players in the beta thalassemia market. Some of the key products in the Beta-thalassemia therapeutics market landscape include Zynteglo (LentiGlobin BB305), Mitapivat, Sapablursen, among others.

DelveInsight’s “Beta-thalassemia (B-thal) Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Beta-thalassemia (B-thal) market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Beta-thalassemia (B-thal) market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Recent highlights in the Beta-thalassemia market:

  • In 2023, the United States had approximately 1.35 million prevalent cases of Beta-thalassemia. Factors contributing to this rise in the 7MM (seven major markets) include improved diagnosis and screening, limited access to genetic counseling and family planning, and a lack of public awareness. 

  • When the cases of Beta-thalassemia in the EU4 (France, Germany, Italy, Spain) and the UK were segmented by type, Beta Thalassemia Major had a higher prevalence compared to Beta Thalassemia Intermedia. In 2023, around 7.39 million individuals were affected by Beta Thalassemia Major, with this number projected to change during the study period from 2020 to 2034.

  • Italy had the highest number of Beta-thalassemia cases in the 7MM, with approximately 3.68 million cases in 2023, expected to change further during the study period. In Spain, Beta Thalassemia Major was the most prevalent type, with about 217,000 cases in 2023. DelveInsight’s analysis projects these numbers to increase during the forecast period from 2024 to 2034.

  • Among the currently approved treatments for Beta-thalassemia, betibeglogene autotemcel is anticipated to achieve the highest market size in the US by 2034. With the expected approval of new therapies during the forecast period, the overall Beta-thalassemia therapeutic market is projected to see significant growth at a substantial compound annual growth rate (CAGR).

Beta-thalassemia (B-thal) Overview

Beta-thalassemia (B-thal) is a hereditary blood disorder characterized by reduced or absent synthesis of the beta chains of hemoglobin, leading to anemia and various complications. It is an autosomal recessive condition caused by mutations in the HBB gene.

Beta-thalassemia (B-thal) Market Growth

The Beta-thalassemia treatment market is poised for growth due to several key factors. Increased investment in research and development by major industry players is driving the discovery of novel therapies. A robust pipeline, bolstered by well-designed trials and collaborations between developers, is accelerating the pace of innovation. Rising prevalence and increased awareness of Beta-thalassemia are expanding the patient pool and driving demand for effective treatments. Enhanced diagnostic techniques allow for earlier and more accurate diagnosis, improving patient outcomes and facilitating efficient clinical trial recruitment. Collectively, these factors create a favorable environment for advancements in Beta-thalassemia treatment options and stimulate growth in the pharmaceutical and biotechnology sectors dedicated to addressing this genetic disorder.

Beta-thalassemia (B-thal) Epidemiology Insights

  • The total prevalent cases of Beta-thalassemia Minor in the US was found to be 1,359 thousands in the year 2023. These cases are expected to change significantly by 2034.

  • The Germany accounted for around 235 thousands prevalent cases of Beta-thalassemia Minor in 2023.

  • In the UK, when Beta-thalassemia cases were categorized by type, a notable disparity was observed, with a higher prevalence of Beta Thalassemia Major compared to Beta Thalassemia Intermedia. In 2023, approximately 745 thousand cases of Beta-thalassemia major were recorded, and these figures are expected to undergo further fluctuations throughout the study period spanning from 2020 to 2034.

  • Among the EU4 and the UK, Italy had the highest prevalent cases of Beta-thalassemia minor with approximately 3,676 thousand cases, followed by Spain with around 772 thousand cases. Projections indicate a substantial change in these cases by the year 2034.

  • In 2023, France had around 678 thousand diagnosed prevalent cases of Beta-thalassemia. These cases are expected to further change by 2034.

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Beta-thalassemia (B-thal) Epidemiology, Segmented as –

  • Total Prevalent Population of Beta Thalassemia (2020–2034)

  • Total Prevalent Cases of Beta Thalassemia Minor (2020–2034)

  • Diagnosed Prevalence of Beta Thalassemia (2020–2034)

  • Diagnosed Beta-Thalassemia Patients by Disease Type (2020–2034)

Beta-thalassemia (B-thal) Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Beta-thalassemia (B-thal) market or expected to be launched during the study period. The analysis covers the Beta-thalassemia (B-thal) market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Beta-thalassemia (B-thal) pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Beta-thalassemia (B-thal) Market Will Evolve and Grow by 2034 @

Beta-thalassemia Marketed Therapies

Reblozyl: Merck/Bristol Myers Squibb

  • In June 2020, Bristol Myers Squibb (BMS) & Acceleron Pharma announced that the European Commission approved Reblozyl (luspatercept) for the treatment of transfusion-dependent β-thalassemia (TDT) in adult patients. This approval was based on data from the pivotal Phase III MEDALIST and BELIEVE studies, evaluating the ability of REBLOZYL to effectively address anemia associated with MDS and Beta Thalassemia, respectively.

EXJADE: Novartis

  • In November 2005, Novartis announced the US Food and Drug Administration (FDA) approval of its new drug application (NDA) for EXJADE to treat chronic iron overload in patients age 2 and older.

  • In January 2020, the US FDA approved Glenmark Pharmaceuticals’ deferasirox tablets for oral suspension, 125 mg, 250 mg, and 500 mg. The drug is the generic version of EXJADE (deferasirox, Novartis) tablets for oral suspension, 125 mg, 250 mg, and 500 mg.

Leading Companies in the Beta Thalassemia Therapeutics Market Include Acceleron Pharma, Agios Pharmaceuticals, Inc., Allife Medical Science and Technology, Aruvant Sciences, Beam Therapeutics, Bioray Laboratories, Bluebird Bio, Bristol Myers Squibb, Chiesi Farmaceutici S.p.A, CRISPR Therapeutics, Disc Medicine, DisperSol Technologies, EdiGene (GuangZhou) Inc., Editas Medicine, EmeraMed, Forma Therapeutics, Fulcrum Therapeutics, Global Blood Therapeutics, Inc, Graphite Bio, Imara, Inc., Ionis Pharmaceuticals, Inc., Merck, Novartis, Orchard Therapeutics, Phoenicia Biosciences, Regenacy Pharmaceuticals, San Rocco Therapeutics, Sangamo Therapeutics, Shanghai BDgene, Silence Therapeutics plc, Vertex Pharmaceuticals, Vifor Pharma, and others.

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @

Table of Contents

1. Key Insights

2. Executive Summary 

3. Beta-thalassemia (B-thal) Competitive Intelligence Analysis

4. Beta-thalassemia (B-thal) Market Overview at a Glance

5. Beta-thalassemia (B-thal) Disease Background and Overview

6. Beta-thalassemia (B-thal) Patient Journey

7. Beta-thalassemia (B-thal) Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Beta-thalassemia (B-thal) Treatment Algorithm, Current Treatment, and Medical Practices

9. Beta-thalassemia (B-thal) Unmet Needs

10. Key Endpoints of Beta-thalassemia (B-thal) Treatment

11. Beta-thalassemia (B-thal) Marketed Products

12. Beta-thalassemia (B-thal) Emerging Drugs and Latest Therapeutic Advances

13. Beta-thalassemia (B-thal) Seven Major Market Analysis

14. Attribute Analysis

15. Beta-thalassemia (B-thal) Market Outlook (In US, EU5, and Japan)

16. Beta-thalassemia (B-thal) Access and Reimbursement Overview

17. KOL Views on the Beta-thalassemia (B-thal) Market

18. Beta-thalassemia (B-thal) Market Drivers

19. Beta-thalassemia (B-thal) Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States